Grant to develop stem cell therapies for people with MS
18 February 2004
This is the MS Society's first funding for stem cell research, and is part of a large portfolio committed to finding its cause and cure and improving the quality of life for people with MS.
Professor Neil Scolding is working on developing therapies for patients with MS that will repair damaged areas in the brain and spinal cord and restore lost functions. There are two serious hurdles for such therapies:
"We now know that adult human bone marrow contains stem cells that can turn into those cell types that repair myelin, the insulating membrane lost in MS", explains Professor Scolding. Additionally, recent research elsewhere suggests that bone marrow stem cells, when delivered into the bloodstream, can find their own way to damaged areas of the brain.
Preliminary studies at Frenchay Hospital, undertaken in collaboration with Professor Jill Hows, have already established that stem cells can be grown in large quantities from adult human bone marrow, and that these can be turned into the types of brain cell which should be able to repair myelin.
The team now hopes to discover whether these cells will indeed repair myelin in collaborative studies with Professors David Wraith and James Uney. They will also assess whether there are any potential risks associated with using adult human stem cells in this way.
Professor Scolding, commenting on his grant, said: "It is extremely generous of the MS Society to offer this support, which represents a further crucial step in the continuing development of MS research and treatment excellence at Frenchay. I am convinced that our studies on adult stem cells will accelerate the development of these important therapies for patients with this difficult and challenging disease."
- finding a suitable cell type to replace lost brain cells
- devising ways of delivering these repair cells to the often large numbers of damaged areas in the brain and spinal cord of people with MS
"We now know that adult human bone marrow contains stem cells that can turn into those cell types that repair myelin, the insulating membrane lost in MS", explains Professor Scolding. Additionally, recent research elsewhere suggests that bone marrow stem cells, when delivered into the bloodstream, can find their own way to damaged areas of the brain.
Preliminary studies at Frenchay Hospital, undertaken in collaboration with Professor Jill Hows, have already established that stem cells can be grown in large quantities from adult human bone marrow, and that these can be turned into the types of brain cell which should be able to repair myelin.
The team now hopes to discover whether these cells will indeed repair myelin in collaborative studies with Professors David Wraith and James Uney. They will also assess whether there are any potential risks associated with using adult human stem cells in this way.
Professor Scolding, commenting on his grant, said: "It is extremely generous of the MS Society to offer this support, which represents a further crucial step in the continuing development of MS research and treatment excellence at Frenchay. I am convinced that our studies on adult stem cells will accelerate the development of these important therapies for patients with this difficult and challenging disease."
